Therapeutic Goods (Charges) Amendment Bill 2026

Summary

This amendment changes the fees and charges that pharmaceutical companies and medical device manufacturers pay when they submit products to the Therapeutic Goods Administration (TGA) for approval and ongoing regulation. The changes modify the Therapeutic Goods Act 1989 by adjusting how much it costs to register medicines, medical devices, and other therapeutic products, as well as fees for annual compliance and inspections. This matters because it directly affects how much companies spend to bring new treatments to Australian patients — higher fees could delay products reaching the market or increase medicine costs, while lower fees might improve access but reduce TGA resources for safety oversight.